Media Research Institute, 3D Matrix, etc.

＜4564＞Number of shares issued from mass exercise of the 36th OTS Stock Acquisition Rights (with exercise price amendment clause), 6 million shares ＜4586＞number of shares issued from mass exercise 1 of the 28th Medlec Stock Acquisition Rights (with exercise price correction clauses), 600,000 shares ＜5256＞FusicAI training systems sold ＜7777＞3D Matrix TDM-623 Apply for approval<9242

Fisco JapanMay 2 06:30

Jade Group, Digital Plus, etc.

＜3558＞Jade Group Co., Ltd. Asset Value Investors Limited (AssetValue Investors Limited) Stock Ownership Ratio 8.33% → 9.43% Reporting Obligation Date 2024/04/18 ＜3691 ＞Digital Plus McCauley Bank Limited Stock Ownership Ratio 15.79% → 14.54% Reporting Obligation Date 2024/04/09＜426

Fisco JapanApr 26 07:52

FINATEXT, TASKI HD, etc.

＜166a＞Acquired shares of Aura, which handles the TASKI HD Asset Consulting business, and made it a subsidiary ＜4419＞FinATEXT upward revision, previous fiscal year operating profit forecast 220 million yen ← 0.21 billion yen ＜4564＞OTS acquisition/cancellation of all remaining 35th stock acquisition rights (with exercise price correction clauses) ＜4586＞Medlec 28th Stock Acquisition Rights (with exercise price correction clauses) from the 11th, 570,000 shares ＜4597＞Number one 14th Stock Acquisition Rights (exercise)

Fisco JapanApr 23 06:30

Tsubota Lab, 3D Matrix, etc.

＜2173＞Hakuten Shareholder Benefit System Changed (Expanded) ＜4564＞Acquisition and Cancellation of All Remaining Stock Acquisition Rights (with Exercise Price Amendment Clauses) of OTS 36th Stock Acquisition Rights Issuance of 36th Stock Acquisition Rights (54 million potential shares, procurement amount approximately 1,029 billion yen) ＜4890＞Tsubota Lab Pipeline “TLG-005” completed inclusion of subjects in specific clinical research on mild dementia (MCI) ＜7777＞3D matrix hemostasis material “purestat” To the surgical field Physicians-led efforts to expand adaptation

Fisco JapanApr 8 06:30

OncoTherapy Science 9-Mos Loss Y987.00M Vs Loss Y913.00M

OncoTherapy Science Inc. (4564.TO) Japan Nine Months Ended December 31 GROUP 2023 2022 Revenue Y466.00 mln Y699.00 mln Operating Profit

Dow JonesFeb 9 16:00

OncoTherapy Science 1H Loss Y710.00M Vs Loss Y613.00M

OncoTherapy Science Inc. (4564.TO) Japan 1st Half Ended September 30 GROUP 2023 2022 Revenue Y356.00 mln Y514.00 mln Operating Profit (Y

Dow JonesNov 10, 2023 16:00